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Omission of doxorubicin from the treatment of stage II–III, 
intermediate-risk Wilms’ tumour (SIOP WT 2001): an 
open-label, non-inferiority, randomised controlled trial
Kathy Pritchard-Jones, Christophe Bergeron, Beatriz de Camargo, Marry M van den Heuvel-Eibrink, Tomas Acha, Jan Godzinski, 
Foppe Oldenburger, Liliane Boccon-Gibod, Ivo Leuschner, Gordan Vujanic, Bengt Sandstedt, Jan de Kraker*, Harm van Tinteren, Norbert Graf, 
on behalf of the SIOP Renal Tumours Study Group
Summary
Background Before this study started, the standard postoperative chemotherapy regimen for stage II–III Wilms’ 
tumour pretreated with chemotherapy was to include doxorubicin. However, avoidance of doxorubicin-related 
cardiotoxicity eﬀ ects is important to improve long-term outcomes for childhood cancers that have excellent prognosis. 
We aimed to assess whether doxorubicin can be omitted safely from chemotherapy for stage II–III, histological 
intermediate-risk Wilms’ tumour when a newly deﬁ ned high-risk blastemal subtype was excluded from randomisation.
Methods For this international, multicentre, open-label, non-inferiority, phase 3, randomised SIOP WT 2001 trial, we 
recruited children aged 6 months to 18 years at the time of diagnosis of a primary renal tumour from 251 hospitals in 
26 countries who had received 4 weeks of preoperative chemotherapy with vincristine and actinomycin D. Children 
with stage II–III intermediate-risk Wilms’ tumours assessed after delayed nephrectomy were randomly assigned (1:1) 
by a minimisation technique to receive vincristine 1·5 mg/m² at weeks 1–8, 11, 12, 14, 15, 17, 18, 20, 21, 23, 24, 26, and 
27, plus actinomycin D 45 μg/kg every 3 weeks from week 2, either with ﬁ ve doses of doxorubicin 50 mg/m² given 
every 6 weeks from week 2 (standard treatment) or without doxorubicin (experimental treatment). The primary 
endpoint was non-inferiority of event-free survival at 2 years, analysed by intention to treat and a margin of 10%. 
Assessment of safety and adverse events included systematic monitoring of hepatic toxicity and cardiotoxicity. This 
trial is registered with EudraCT, number 2007-004591-39, and is closed to new participants. 
Findings Between Nov 1, 2001, and Dec 16, 2009, we recruited 583 patients, 341 with stage II and 242 with stage III 
tumours, and randomly assigned 291 children to treatment including doxorubicin, and 292 children to treatment 
excluding doxorubicin. Median follow-up was 60·8 months (IQR 40·8–79·8). 2 year event-free survival was 92·6% 
(95% CI 89·6–95·7) for treatment including doxorubicin and 88·2% (84·5–92·1) for treatment excluding doxorubicin, 
a diﬀ erence of 4·4% (95% CI 0·4–9·3) that did not exceed the predeﬁ ned 10% margin. 5 year overall survival was 
96·5% (94·3–98·8) for treatment including doxorubicin and 95·8% (93·3–98·4) for treatment excluding doxorubicin. 
Four children died from a treatment-related toxic eﬀ ect; one (<1%) of 291 receiving treatment including doxorubicin 
died of sepsis, three (1%) of 292 receiving treatment excluding doxorubicin died of varicella, metabolic seizure, and 
sepsis during treatment for relapse. 17 patients (3%) had hepatic veno-occlusive disease. Cardiotoxic eﬀ ects were 
reported in 15 (5%) of 291 children receiving treatment including doxorubicin. 12 children receiving treatment 
including doxorubicin, and ten children receiving treatment excluding doxorubicin, died, with the remaining deaths 
from tumour recurrence. 
Interpretation Doxorubicin does not need to be included in treatment of stage II–III intermediate risk Wilms’ tumour 
when the histological response to preoperative chemotherapy is incorporated into the risk stratiﬁ cation. 
Funding See Acknowledgments for funders. 
Copyright © Pritchard-Jones et al. Open Access article distributed under the terms of CC BY.
Introduction
Wilms’ tumour (or nephroblastoma) is an embryonal 
kidney cancer that aﬀ ects about 1 in 10 000 children, with 
90% of cases occurring before the age of 7 years.1 
Treatment of localised, non-anaplastic Wilms’ tumour, 
which accounts for nearly three-quarters of all cases, is 
highly successful, with a cure rate of almost 90%.2–5 
Treatment consists of nephrectomy and chemotherapy, 
together with radiotherapy when the tumour is classiﬁ ed 
as stage III. Chemotherapy regimens have not changed 
much since the late 1990s—vincristine and actinomycin D 
are used for nearly all patients. Doxorubicin is added to 
postoperative chemotherapy for stage III tumours after 
immediate nephrectomy (the approach of the North 
American Children’s Oncology Group), and for stage II 
and III tumours after preoperative chemotherapy (the 
approach of the International Society of Paediatric 
Oncology Renal Tumours Study Group [SIOP-RTSG]). 
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Overall, 33–40% of all patients with unilateral, localised, 
non-anaplastic Wilms’ tumour receive doxorubicin.3,5,6
In the setting of such a highly curable childhood 
cancer, the reduction of potential harm from irreversible 
side-eﬀ ects of treatment is of paramount importance 
to improve overall outcomes.7–9 Survival from Wilms’ 
tumour has been increasing over the past 40 years, while, 
paradoxically, the overall duration and intensity of 
treatment has been decreasing for most patients.2,4 This 
ﬁ nding suggests that further treatment reductions could 
be possible for many patients.
The potential for doxorubicin to cause clinically 
signiﬁ cant cardiac disease after treatment for childhood 
cancers has long been recognised; in some patients this 
cardiac disease can ﬁ rst manifest itself more than 
20 years after treatment.10,11 Although the risk of 
cardiotoxicity is related to the total cumulative dose of 
doxorubicin, there is probably no completely safe dosing 
schedule for doxorubicin,11,12 especially in very young 
patients who are typically aﬀ ected by Wilms’ tumour 
(median age at diagnosis 3–4 years). In the SIOP WT 
2001 trial, we therefore investigated the outcome of 
complete removal of doxorubicin rather than a dose 
reduction in the relevant regimens.
The SIOP approach of neoadjuvant treatment of 
Wilms’ tumour provides a unique opportunity to assess 
the in-vivo histological response of each child’s tumour. 
Tumours are subtyped according to the proportion of 
necrosis and the cellular composition of the residual 
viable tumour.13 Results from a retrospective analysis of 
the SIOP 9 and 93-01 trials14,15 showed that patients 
with blastemal-type Wilms’ tumour—of which a high 
proportion of any surviving viable tumour after 
preoperative chemotherapy consists of undiﬀ erentiated 
tumour cells—have a signiﬁ cantly worse chance of 
event-free survival compared with patients with other 
subtypes of histologically determined intermediate-risk, 
non-anaplastic Wilms’ tumour. Therefore, we classiﬁ ed 
the blastemal subtype as high-risk histology, and we 
excluded patients with this subtype, and the diﬀ use 
anaplastic subtype, from the randomised trial.16
We aimed to assess whether doxorubicin could be 
safely removed from the treatment of intermediate-risk 
(as determined by histology), stage II–III Wilms’ tumours 
after preoperative chemotherapy.
Methods
Study design and participants
We did an international, multicentre, unmasked, 
randomised, non-inferiority trial in 251 hospitals in 
26 countries (appendix). A description of the trial 
protocol is available online. National and local regulatory 
and ethical approvals were obtained according to 
national regulations.
We recruited patients aged between 6 months and 
18 years at diagnosis of a primary intrarenal tumour 
for randomisation of their postoperative chemotherapy. 
Patients had to have received preoperative chemotherapy 
of 4 weeks of vincristine and actinomycin D as per 
protocol, and have a stage II–III intermediate-risk (as 
determined by histology) Wilms’ tumour when assessed 
at delayed nephrectomy by the institutional pathologist.16 
We excluded patients with high-risk blastemal or diﬀ use 
anaplastic subtypes, or evidence of metastases, and 
patients who had been given an immediate nephrectomy 
or who had not received protocol-deﬁ ned preoperative 
chemotherapy, or whose legal guardians did not consent 
to the randomisation. Rapid central review of tumour 
stage and histological subtype was encouraged and 
available in all participating countries but was not 
mandated before randomisation.
The parents or legal guardians of all patients gave 
written informed consent at diagnosis for registration in 
the study, and after nephrectomy for the randomisation, 
when details about the tumour stage and histological risk 
group were available from the institutional pathologist.
Randomisation and masking
Patients’ eligibility for randomisation after nephrectomy 
was assessed according to the local institutional 
pathologist’s decision about tumour stage and histological 
risk group, and this information was submitted on a 
randomisation request form. We randomly assigned 
patients (1:1) to receive chemotherapy either with or 
without doxorubicin via a central computer system over 
the internet (ALEA, Netherlands Cancer Institute, 
Amsterdam, Netherlands) by a minimisation technique, 
stratiﬁ ed by trial oﬃ  ce (Brazil, France, Germany, UK, and 
the SIOP-Amsterdam oﬃ  ce for all other countries) and 
pathological stage (II or III). All patients, treating 
clinicians, and those assessing outcomes and analysing 
the data were unmasked to treatment allocation. 
Procedures
We used the revised SIOP tumour staging system and 
histological risk classiﬁ cation (appendix) to classify 
tumours.13 A percutaneous cutting needle biopsy 
(18 gauge) was allowed without aﬀ ecting tumour stage. 
This biopsy was done routinely to conﬁ rm histological 
abnormalities before starting chemotherapy only in 
patients treated in the UK and Ireland, according to 
national practice.17 All other countries continued the well 
established SIOP approach of starting preoperative 
chemotherapy on the basis of clinical and imaging 
characteristics consistent with a diagnosis of Wilms’ 
tumour, combined with measuring urinary catecho-
lamines to exclude neuroblastoma, and reserving biopsy 
for cases with diagnostic dilemma.2,18,19
Three-dimensional tumour volume was recorded at 
diagnosis and after completion of preoperative 
chemotherapy, according to whichever imaging method 
had been applied (ultrasonography, CT scan, or MRI 
scan). The calculated volume showed close correlation 
between methods (appendix). In Germany, children 
See Online for appendix
For trial proﬁ le see http://www.
cancerresearchuk.org/about-cancer/
ﬁ nd-a-clinical-trial/a-trial-looking-
at-treatment-for-children-and-
young-people-with-kidney-cancer-
including-wilms-tumour 
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whose tumour volume after preoperative chemotherapy 
was larger than 500 mL were classiﬁ ed as high risk and 
excluded from random assignment unless they had 
stromal or epithelial-type Wilms’ tumours—subtypes 
that do not shrink but do have a good prognosis.3,20
We gave all patients the same preoperative chemo-
therapy of vincristine 1·5 mg/m² intravenously every 
week combined with actinomycin D 45 μg/kg intra-
venously every 2 weeks for 4 weeks, followed by 
unilateral nephrectomy, for which lymph node sampling 
was recommended but not mandatory. Randomly 
assigned patients received postoperative chemotherapy 
for 27 weeks. The treatment including doxorubicin 
consisted of vincristine 1·5 mg/m² (maximum dose 
2 mg) intravenous bolus each week for weeks 1–8, then 
at weeks 11, 12, 14, 15, 17, 18, 20, 21, 23, 24, 26, and 27, 
combined with actinomycin D 45 μg/kg (maximum 
dose 2 mg) intravenous bolus every 3 weeks from 
week 2, and ﬁ ve doses of doxorubicin 50 mg/m² in 
4–6 h infusions (total dose 250 mg/m²) given once every 
6 weeks from week 2. The treatment excluding 
doxorubicin omitted doxorubicin entirely and consisted 
of the identical backbone of vincristine and 
actinomycin D only (with the same doses and timing). 
We reduced the dose for all drugs in patients who 
weighed less than 12 kg (two-thirds of the standard 
dose). We recommended that children with stage III 
Wilms’ tumour receive ﬂ ank radiotherapy (14·4 Gy) 
with a 10 Gy boost to locoregional lymph nodes with 
microscopic tumour involvement or any sites of 
macroscopic residual tumour, or whole abdominal 
radiotherapy (21 Gy) if gross tumour rupture had 
occurred. We modiﬁ ed chemotherapy scheduling 
accordingly to avoid concurrent radiotherapy with 
doxorubicin or actinomycin D.
We ascertained patient demographic characteristics, 
tumour characteristics and response, treatments given, 
adverse events, and outcomes from standard case 
report forms completed at registration, the end of 
preoperative chemotherapy, after nephrectomy, at the 
end of treatment, and annually thereafter or at the time 
of any event. These were submitted to one of 
ﬁ ve national trial oﬃ  ces in Brazil, France, Germany, the 
Netherlands, and the UK. The Netherlands trial oﬃ  ce 
(SIOP-NL) registered patients from all other par-
ticipating countries and held the master trial database 
that received 6 monthly data transfers from the other 
trial oﬃ  ces. Spain started a national trial oﬃ  ce in 
March, 2007, but was not deemed as a separate oﬃ  ce 
for stratiﬁ cation of randomisation because of the few 
cases randomised in the time period. We assessed 
safety and adverse events through speciﬁ c sections in 
the case report forms.
Outcomes
The primary endpoint of the trial was to test the 
non-inferiority of 2 year event-free survival between 
treatment including doxorubicin versus treatment 
excluding doxorubicin. Secondary outcomes were 5 year 
event-free survival and 5 year overall survival.
Both treatment regimens are well tolerated,15 hence our 
assessment of safety and adverse events focused on 
systematic monitoring of hepatic toxicity and cardiotoxicity, 
which are infrequent but sometimes serious side-eﬀ ects 
of actinomycin D (hepatic toxic eﬀ ects) and doxorubicin 
(cardiotoxic eﬀ ects).
Figure 1: Trial proﬁ le
AVD=actinomycin plus vincristine plus doxorubicin. AV2=actinomycin plus vincristine only (no doxorubicin).
2243 children were registered. 1061 had documented 
 stage II–III Wilms’ tumour, of which 845 were 
 intermediate-risk histology
89 excluded because they had incorrect stage or histological 
 findings at randomisation or after central pathological review, 
 received treatment including doxorubicin (n=33), or did not 
 receive radiotherapy (n=14 stage III); some excluded patients 
 were in more than one category
583 randomised
221 included in per-protocol analysis 203 included in per-protocol analysis
291 included in intention-to-treat analysis 292 included in intention-to-treat analysis
292 assigned to AV2 treatment excluding doxorubicin291 assigned to AVD treatment including doxorubicin
262 not randomised
70 excluded because they had incorrect stage or histological 
 findings at randomisation or after central pathological review, 
 did not receive treatment including doxorubicin (n=12), or did 
 not receive radiotherapy (n=14 stage III); some excluded 
 patients were in more than one category
Articles
www.thelancet.com   Vol 386   September 19, 2015 1159
Statistical analysis
We assumed a 2 year event-free survival of 86%, with a 
non-inferiority margin of 10%, 5% type I error, and 80% 
power, and estimated that at least 350 patients would need 
to be included in our study.21 Our assumption of 86% 
event-free survival was based on the data from the SIOP 
93-01 study,3 in which two-thirds of potentially eligible 
patients had stage II (2 year event-free survival 88%) and a 
third had stage III (2 year event-free survival 83%) Wilms’ 
tumour, and in which blastemal-type Wilms’ tumour 
would have been included within intermediate-risk 
histology because its recognition was not required by the 
local pathologist. However, since this subtype includes less 
than 9% of all localised Wilms’ tumours, its removal would 
be unlikely to have a major eﬀ ect on the predicted numbers 
for the calculation of sample size. We estimated that 
patient accrual would take 7 years, and another 2 years of 
follow-up would be needed to analyse the data at full power. 
The trial reached its target sample size early (Nov 6, 2006). 
Hence, the trial management group, in conjunction with 
the Independent Data Monitoring Committee review of 
the Feb 17, 2007, interim analysis, agreed to increase the 
sample size to 550 randomly assigned patients to provide 
about 104 events for an increased power of 90% and a 
reduction in the type I error to 0·025 (one sided) to improve 
the reliability of the overall results and to allow separate 
analysis of stage II and III tumours.
The intention-to-treat analyses included all randomly 
assigned patients. The primary endpoint of 2 year 
event-free survival was ﬁ rst analysed when the last 
randomly assigned patient had a minimum of 2 years of 
follow-up. Event-free survival was calculated from the date 
of randomisation to the date of recurrence or death, 
whichever happened ﬁ rst. Patients alive and without 
recurrence were censored at their last date of follow-up. 
We tested non-inferiority at 2 years with the Kaplan-Meier 
estimator of the survival proportion with an absolute 10% 
margin, with Greenwood’s variance estimator for the 
diﬀ erence between two survival proportions.22,23 Kaplan-
Meier survival curves (not restricted to 2 years) are 
presented with 95% CIs. Cox proportional hazard ratios 
(HRs) were calculated for the overall groups and for 
diﬀ erent subgroups (stage and national trial oﬃ  ce). The CI 
of the HR was provided to show the precision of the 
estimate, not to assess non-inferiority. We assessed the 
assumption of proportional hazards by use of Schoenfeld 
residuals and by testing a time-dependent covariate, 
deﬁ ned as the interaction between treatment group and 
log survival time. We did a test for interaction to explore 
heterogeneity in subgroups, and also calculated the 
number needed to treat based on survival probabilities and 
HR estimates. We calculated overall survival from the date 
Treatment 
including 
doxorubicin 
(n=291)
Treatment 
without 
doxorubicin 
(n=292)
Estimated 
eligible but 
not 
randomised 
(n=262)
Sex
Male 138 (47%) 138 (47%) 47%
Female 153 (53%) 154 (53%) 53%
Age (months) 38 (25–54) 41 (25–57) 41 (26–57)
Study group
Grupo Cooperativo 
Brasileiro para o 
Tratamento do Tumor de 
Wilms
62 (21%) 64 (22%) 16%
Gesellschaft fü r 
Pädiatrische Onkologie 
und Hämatologie
45 (15%) 45 (15%) 17%
Société Française des 
Cancers de l’Enfant
76 (26%) 74 (25%) 23%
International Society of 
Paediatric Oncology 
Netherlands
63 (22%) 65 (22%) 23%
Children’s Cancer and 
Leukaemia Group
45 (15%) 44 (15%) 21%
Stage of Wilms’ tumour at 
randomisation
II 170 (58%) 171 (59%) 55%
III 121 (42%) 121 (41%) 45%
Data are n (%), %, or median (IQR). The ﬁ nal column shows the demographic 
characteristics of the estimated 262 patients with stage II or stage III tumours 
and intermediate-risk histology (after pathological review) who were not 
randomly assigned.
Table 1: Baseline characteristics of the intention-to-treat population 
Treatment 
including 
doxorubicin 
(n=291)
Treatment 
without 
doxorubicin 
(n=292)
Stage of Wilms’ tumour
I 33 (11%) 42 (14%)
II 147 (51%) 133 (46%)
III 109 (37%) 113 (39%)
IV 1 (<1%) 4 (1%)
Information unavailable 1 (<1%) 0 (0%)
Low-risk group 4 (1%) 2 (<1%)
Completely necrotic 4 (1%) 2 (<1%)
Intermediate-risk group 276 (95%) 279 (96%)
Intermediate risk (not otherwise 
speciﬁ ed)
9 (3%) 3 (1%)
Epithelial 15 (5%) 14 (5%)
Stromal 35 (12%) 35 (12%)
Mixed 112 (38%) 90 (31%)
Regressive 102 (35%) 131 (45%)
Focal anaplasia 3 (1%) 6 (2%)
High-risk group 5 (2%) 9 (3%)
Blastemal 2 (1%) 9 (3%)
Diﬀ use anaplasia 3 (1%) 0 (0%)
Not assessed or non-Wilms 6 (2%) 2 (1%)
Data are n (%), analysed according to central pathological review.
Table 2: Tumour stage and histological risk groups 
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of random assignment to the date of death (all causes), and 
did several per-protocol analyses to test the robustness 
of the results. Our per-protocol analysis included only 
patients whose tumours were stage II or III, had 
intermediate-risk histology after a central pathological 
review, and who had received the treatment to which they 
had been randomly assigned. Stage III patients who 
received no radiotherapy were excluded from the 
per-protocol analysis. Long-term follow-up is in progress. 
We used the statistics programs SAS version 9.2 and 
R version 3.1.1 for all analyses. 
This trial is registered with EudraCT, number 
2007-004591-39.
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication.
Results
Between Nov 1, 2001, and Dec 16, 2009, we recruited 
2243 children with unilateral, non-metastatic Wilms’ 
tumour for the SIOP WT 2001 trial and study. Of 
845 (80%) with documented intermediate-risk hist -
ology stage II–III Wilms’ tumour after preoperative 
chemotherapy according to the protocol, 583 (69%) 
patients were randomly assigned to postoperative 
chemotherapy: 292 to treatment excluding doxorubicin 
and 291 to treatment including doxorubicin (ﬁ gure 1). 
All 583 patients were included in the intention-to-treat 
analysis. Baseline characteristics were similar between 
groups (table 1), but slightly more patients than predicted 
from the previous trial3 had stage III tumours.
580 cases (99%) were submitted for central 
pathological review, 555 (96%) of which were conﬁ rmed 
as intermediate-risk histology and 502 (87%) of which 
were conﬁ rmed as stage II–III (table 2). The distribution 
of the few patients who were ineligible because of 
adverse tumour factors (stage IV and high-risk 
histology) after pathological review did not diﬀ er 
signiﬁ cantly. For patients who had details available of 
postoperative treatment of the high-risk tumours, nine 
of 14 had their postoperative treatment intensiﬁ ed to 
take account of the review information.
Median follow-up was 60·8 months (IQR 40·8–79·8) for 
all randomly assigned patients. 39 events (including 
36 relapses) occurred in the group without doxorubicin 
compared with 26 events (24 relapses) in the group with 
doxorubicin. The absolute diﬀ erence in event-free survival 
at 2 years was 4·4% (95% CI 0·4–9·3), which did not 
surpass the predeﬁ ned limit (table 3). The 2 year estimates 
of event-free survival were 88·2% (95% CI 84·5–92·1) 
without doxorubicin versus 92·6% (89·6–95·7) with 
doxorubicin. 22 patients would need to receive doxorubicin 
to prevent one relapse (appendix).
We noted no signiﬁ cant diﬀ erences between the groups 
for 5 year event-free survival or 5 year overall survival 
(table 3, ﬁ gure 2). The HR for any event was 1·55 
(95% CI 0·94–2·54) and for death was 0·81 (0·35–1·89). 
Only three ﬁ rst relapses happened after 5 years, all in the 
group receiving doxorubicin.
424 patients met the criteria for the per-protocol 
analysis. We noted a small increase in the size of the 
absolute diﬀ erence in 2 year event-free survival in the 
per-protocol population (table 3). The number needed to 
treat with doxorubicin to prevent one excess relapse 
remained at about 22 patients (ﬁ gure 2).
When outcome was analysed separately by tumour 
stage, the diﬀ erences in 2 year event-free survival (table 3) 
and corresponding increase in HR for any event were 
similar for stage II and stage III tumours. We also did 
Kaplan-Meier survival curve analyses for events over the 
entire time course (appendix).
17 (3%) patients had hepatic veno-occlusive disease, 
11 during preoperative chemotherapy and eight during 
postoperative chemo therapy, with two patients having 
more than one episode of veno-occlusive disease. 
Four (<1%) children, all from Brazil, died after treatment-
related toxic eﬀ ects: three in ﬁ rst remission (one from 
neutropenic sepsis who received treatment including 
doxorubicin, and one each from varicella and metabolic 
seizure, both of whom received treatment excluding 
Treatment including 
doxorubicin
Treatment without 
doxorubicin
Diﬀ erence 
(95% CI)
Intention-to-treat population (n=583) n=291 n=292
2 year event-free survival 92·6%, 89·6–95·7 88·2%,84·5–92·1 4·4 (0·4–9·3)
Number of events by 2 years 21 (7%) 33 (11%)
5 year event-free survival 91·8%, 88·6–95·1 85·3%, 81·0–89·7
Number of events between 2–5 years 2 (<1%) 6 (2%)
5 year overall survival 96·5%, 94·3–98·8 95·8%, 93·3–98·4
Pathology-reviewed stage II/III Wilms’ 
tumour) (n=502) 
n=256 n=246
Stage II n=147 n=133
2 year event-free survival 92·5%, 88·3–96.8 88·1%, 82·7–94·0 4·3 (2·8 –11·4)
5 year event-free survival 91·6%, 87·1–96·3 84·8%, 78·4–91·7
5 year overall survival 97·6%, 95·0–100·0 95·5%, 91·7–99·5
Stage III n=109 n=113
2 year event-free survival 91·5%, 86·3–97·0 86·9%, 80·8–93·6 4·5 (3·8–12·8)
5 year event-free survival 90·5%, 85·0-96·3 85·1%, 78·3–92·6
5 year overall survival 93·8%, 89·1–98·8 96·0%, 91·5–100·0
Per-protocol analysis* (n=424) n=221 n=203
2 year event-free survival 92·7%, 89·3–96·2 87·8%, 83·3–92·5 4·9 (0·8–10·7)
5 year event-free survival 91·6%, 88·0–95·4 84·8%, 79·6–90·3
5 year overall survival 96·9%, 94·5–99·4 96·0%, 93·0–99·2
Data are %, 95% CI, or n (%). *Several per-protocol analyses are recommended in non-inferiority studies to test the 
sensitivity of any potential diﬀ erence between two groups. Here, the analysis is restricted to only fully compliant 
patients who had the correct diagnosis of stage II or III and intermediate-risk histology tumour after a central 
pathological review, and who received the correctly assigned treatment. Patients with stage III tumours who did not 
receive radiotherapy were also excluded.
Table 3: Event-free and overall survival for the intention-to-treat and per-protocol populations 
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doxorubicin) and one from sepsis during treatment for 
relapse (initially given treatment excluding doxorubicin). 
15 children had cardiotoxic eﬀ ects, maximum grade 1 in 
11 cases and grade 2 in four cases, all in the group with 
doxorubicin.
Most relapses (83%) occurred within 2 years of 
diagnosis in both treatment groups (table 4). 85% of 
stage III tumours received irradiation, with equal 
distribution between the two groups (appendix). Details 
of relapse therapy were reported in 41 of 60 cases. No 
child received further doxorubicin after assigned 
treatment with doxorubicin, whereas doxorubicin was 
given to 11 children relapsing after the assigned treatment 
with no doxorubicin.
Discussion
Our results show that omission of doxorubicin from the 
postoperative chemotherapy regimen of vincristine and 
actinomycin D for patients with stage II and stage III 
Wilms’ tumours of intermediate-risk histological subtype 
was not signiﬁ cantly worse in clinical terms than 
standard treatment with all three drugs, with only a small 
decrease in event-free survival (panel). 5 year overall 
survival was unaﬀ ected by omission of doxorubicin, and 
remained high.
Figure 2: Kaplan-Meier survival curves for event-free survival and overall survival
Data from the intention-to-treat population for event-free survival (A) and overall survival (B) and from the per-protocol population for event-free survival (C) and 
overall survival (D). EFS=event-free survival. OS=overall survival. Per-protocol population includes patients who had eligible tumour stage and histology according to 
review pathology, and correctly received their assigned treatment. 
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2 year EFS including doxorubicin: 92·6% (95% CI 89·6–95·7)
2 year EFS excluding doxorubicin: 88·2% (95% CI 84·5–92·1)
2 year OS including doxorubicin: 98·2% (95% CI 96·6–99·8)
2 year OS excluding doxorubicin: 98·6% (95% CI 97·2–100·0)
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Treatment including doxorubicin
Treatment excluding doxorubicin
Treatment 
including 
doxorubicin 
(n=291)
Treatment 
excluding 
doxorubicin 
(n=292)
Relapses 24 (8%) 36 (12%)
Local recurrence only 3 (1%) 8 (3%)
Haematogenous relapse only* 17 (6%) 17 (6%)
Combined local and 
haematogenous relapses
2 (<1%) 8 (3%)
Relapses with a site missing 2 (<1%) 3 (<1%)
Data are number of patients (%). *23 lung only, three liver only, two lung and liver, 
four lung and other extra-abdominal sites, and two extra-abdominal sites only.
Table 4: Sites of relapse in the intention-to-treat population
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Risk stratiﬁ cation that includes an individualised 
histological assessment of tumour response in vivo has 
allowed further optimisation of the overall burden of 
treatment for children with Wilms’ tumours given 
preoperative chemotherapy followed by delayed 
nephrectomy, by reducing the proportion of patients for 
whom doxorubicin is indicated in their postoperative 
chemotherapy. The results of this trial have changed the 
practice of the SIOP Renal Tumours Study Group. 
However, patients with stage II–III Wilms’ tumours of 
high-risk blastemal type should continue to be given 
doxorubicin.
Although doxorubicin has been included in standard 
chemotherapy regimens since the 1980s for patients with 
stage III Wilms’ tumour, no conclusive evidence has 
shown that front-line doxorubicin treatment improves 
survival.26 Two randomised trials begun in the 1980s 
(National Wilms Tumor Study Group 3 [NWTSG 3] and 
SIOP-6)19,25 tested the removal of doxorubicin from post-
nephrectomy chemotherapy for stage II and stage III 
Wilms’ tumour. Randomisation in SIOP 6 was closed 
early because of an excess of relapses in the treatment 
groups without doxorubicin, but no diﬀ erence in overall 
survival was found in the ﬁ nal analysis of stage II cases 
with lymph node involvement and stage III cases. In 
NWTSG 3,19 a numerical survival advantage for 
doxorubicin was noted only in patients with stage III 
disease who were randomly assigned to a reduced dose 
(10·8 Gy) of ﬂ ank radiotherapy. In both studies, few 
patients were included in the doxorubicin groups and no 
diﬀ erence in overall survival was detected after long-term 
follow-up.
The absence of superior outcomes in previous trials 
that were restricted in statistical power, and the increasing 
recognition of the late adverse eﬀ ects associated with 
doxorubicin therapy, suggested that the role of 
doxorubicin in the management of some patients with 
localised, non-anaplastic Wilms’ tumour should be 
reassessed. Our trial incorporated new information about 
the risk of relapse, according to histological response, 
into the initial risk-stratiﬁ cation process. Although none 
of the survival endpoints reached signiﬁ cance in this 
treatment-reduction setting, reliable quantiﬁ cation of the 
potential risk of excess relapse from omission of a drug 
that might impair long-term quality of life and survival 
was important. We therefore did several per-protocol 
analyses to test the robustness of the results.
The most conservative included an analysis of patients 
whose eligibility of stage II–III, intermediate-risk 
histology Wilms’ tumour was conﬁ rmed by central 
pathological review, taking account of the treatment 
received. By maximising any potential treatment eﬀ ect, 
these analyses helped to support the robustness of our 
ﬁ ndings. The trial could not be adequately powered to 
analyse outcomes separately by tumour stage because of 
the few expected events, even in a large multinational 
trial. However, we did this analysis to explore any signs 
of a diﬀ erential eﬀ ect and showed that omission of 
doxorubicin was not signiﬁ cantly worse in clinical 
terms-for patients with stage II or stage III intermediate-
risk histology. Our data for stage II tumours are similar 
to a longer-term analysis of outcome of stage II tumours 
staged after immediate nephrectomy in the NWTSG 4 
trial,27 for which two-drug (vincristine plus actinomycin D) 
chemotherapy without doxorubicin was the standard 
after the NWTSG 3 trial.19 This previous analysis focused 
on mechanical factors (tumour spill) to stratify stage II 
patients, whereas our study used in-vivo histological 
responses and would have placed tumours with spill into 
stage III. Encouragingly, our data suggest that stage III 
tumours can be treated eﬀ ectively without doxorubicin, 
whereas the Children’s Oncology Group recommend 
that tumours with spill should receive doxorubicin.28
The applicability of our results is restricted to patients 
with Wilms’ tumour given preoperative chemotherapy, 
which is standard clinical practice in most European and 
many other countries. Furthermore, the ultimate goal of 
showing avoidance of symptomatic cardiotoxicity needs 
more than 20 years of follow-up, which is in progress. 
However, the overall beneﬁ t of doxorubicin in the 
long-term outcomes of children with Wilms’ tumour has 
Panel: Research in context
Systematic review
Much debate has been generated regarding treatment schedules that omit anthracyclines 
in Wilms’ tumour; however there are few data. At the time of designing the SIOP WT 2001 
trial in 2000–01, members of the steering committee undertook an extensive review of 
the scientiﬁ c literature in English and several other European languages, on anthracycline 
cardiotoxicity in relation to dose scheduling and toxicity in all types of cancer in both 
children and adults (appendix). They concluded that there was probably no completely 
safe dosing schedule and a design that tested the omission of doxorubicin was preferred. 
The recognition of a new type of high-risk Wilms’ tumour—blastemal type—enabled the 
deﬁ nition of a group of intermediate-risk histology tumours with a lower risk of relapse.14 
This group might therefore be able to avoid doxorubicin without a higher relapse rate. 
A previous Cochrane review24 that assessed treatment including anthracyclines versus 
treatment not including anthracyclines for childhood cancers identiﬁ ed two randomised 
trials that have been done for Wilms’ tumour. One of the trials (SIOP-6)25 was excluded 
from the formal analysis because a 25% diﬀ erence was noted between the study groups in 
cumulative dose of treatments other than anthracyclines. In the other study (National 
Wilms Tumor Study Group 3),19 children were randomly assigned with a 2×2 factorial 
design that compared treatment with or without doxorubicin, and included random 
assignment to diﬀ erent radiation doses of 10 or 20 Gy (K2 or DD2) in stage III, or 0 or 
20 Gy in stage II Wilms’ tumours, after immediate nephrectomy. None of the studies used 
histological assessment of the tumour as a stratiﬁ cation technique. 
Interpretation
To our knowledge, ours is the ﬁ rst randomised study to test, in isolation, omission of 
doxorubicin from the postoperative treatment of stage II–III, intermediate-risk histology 
Wilms’ tumour. Our results build on the long-term follow-up of the SIOP-6 and NWTSG 3 
trials, add to the evidence base that doxorubicin is not necessary for optimum control of 
stage II or III Wilms’ tumours without high-risk histological features after preoperative 
chemotherapy, and emphasise the need for further research into the molecular drivers of 
chemotherapy resistance in the blastemal component of Wilms’ tumour.
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also been questioned by investigators in North America, 
who use an immediate nephrectomy approach as 
standard.29 Nonetheless, doxorubicin is still thought to 
contribute to eﬀ ectiveness in some settings, including 
high-risk blastemal-type Wilms’ tumour30 and metastatic 
disease, even when the metastatic volume is low and 
detectable only by CT.31 Anthracyclines cause dose-related 
cardiotoxicity, and cause an additive eﬀ ect in left-sided 
stage III tumours in which ﬂ ank irradiation might 
encompass part of the heart muscle.10,11 International 
follow-up guidelines suggest that survivors who receive at 
least 250 mg/m² of doxorubicin—the dose given in our 
three-drug regimen—need continual cardiac surveillance. 
Hence, omission of doxorubicin could remove a perpetual 
reminder of possible ill health as a result of treatment for 
Wilms’ tumour survivors who are otherwise healthy.
Because of the complexity of the histological 
composition of Wilms’ tumours, the personalised 
response of each tumour was not based only on the 
percentage of necrosis after preoperative chemotherapy, 
but also on the predominant cell type in the residual 
viable component.13,30 When the percentage of viable 
tumour consists of more than two-thirds primitive 
blastemal cells, in the setting of less than two-thirds 
necrosis, the tumour is classiﬁ ed as high-risk blastemal-
type Wilms’ tumour. These patients were excluded from 
random assignment and continued to receive doxorubicin. 
However, this histological classiﬁ cation is subjective and 
the accuracy of risk stratiﬁ cation needs to be improved; a 
quantitative assessment of the total volume of residual 
blastema after preoperative chemotherapy might achieve 
such accuracy. Preliminary analyses suggest residual 
blastema might be an adverse prognostic factor in this 
solid tumour, akin to measuring low residual disease in 
childhood leukaemia.30 Alternative avenues of research 
are characterisation of molecular biomarkers associated 
with chemotherapy-resistant blastema, with whole-exome 
sequencing and other assessments in progress.32
Our results show that incorporation of a measure of the 
in-vivo chemosensitivity of each child’s tumour into risk 
stratiﬁ cation has allowed further reduction of treatment 
intensity for children with localised, stage II or III Wilms’ 
tumour in a controlled way. Although the small excess of 
relapses in the reduced treatment arm did not lead to a 
rise in the number of deaths even in the long term, a few 
additional children might need treatment for relapse. 
More accurate prognostic risk predictors are needed, and 
the identiﬁ cation of novel molecular, histological, and 
clinical33 risk factors is a priority to allow further 
stratiﬁ cation of treatment intensity.
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